MedTrace Logo

Auditory Functions in Patients With Migraine

NCT04575623 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-02-01

No results posted yet for this study

Summary

Migraine is a neurological disease associated with an altered cortical excitability level . The prevalence of migraine is10.5% of adults in Assiut governorate, and is more frequent in women and in individuals with higher education level . There is evidence that migraine patients could present cognitive deficits, being the affected functions memory, processing information speed and attention. It was found that the prevalence of migraine in AlQuseir was 4.8/100 and the highest figures found during early adult life(18-40) years old .Patients with migraine found to perform significantly worse in duration pattern test(DPT),non-verbal dichotic test ,speech in noise (SPIN)test and found to have longer p300 frequency stimulus latency which indicate presence of cognitive and central auditory processing dysfunction

Conditions

Interventions

DIAGNOSTIC_TEST

Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/

Central auditory function evaluation including: * Duration Pattern test (DPT) designed to test temporal ordering abilities. * Dichotic Digits Test (DDT) it assesses binaural integration skills. * Auditory fusion test-revised (ART-R) to measure temporal resolution. * speech in test to assess central auditory function.

DEVICE

Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.

Cognitive function evaluation including: -Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing. Equipment: * Dual band pure tone audiometer (Orbiter 992). * Impedance audiometer (AT 235h). * Sound treated booth (industrial acoustic company IAC model 1602-A-t) * Panasonic stereo CD player SA-AK 240.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-10-01
Completion
2023-10-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575623 on ClinicalTrials.gov